Urol. praxi, 2011; 12(5): 298-300

Gastrointestinal toxicity after radiation therapy for prostate cancer

MUDr.Milana Šachlová, CSc., Ph.D.1, MUDr.Martin Ondrák, Ph.D.2, MUDr.Ivo Novotný, CSc.1, Vlastimil Polko, DiS.3
1 Gastroenterologické oddělení, Masarykův onkologický ústav, Brno
2 Oddělení chirurgické onkologie, Masarykův onkologický ústav, Brno
3 Oddělení radiologické fyziky, Masarykův onkologický ústav, Brno

The gastrointestinal toxicity is an important dose-limiting factor of prostate cancer treatment. The gastrointestinal toxicity can affect

the quality of life in patiens after radiotherapy. We review the concept of treating such patiens.

Keywords: toxicity, proctitis, radiotherapy, prostate cancer

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šachlová M, Ondrák M, Novotný I, Polko V. Gastrointestinal toxicity after radiation therapy for prostate cancer. Urol. praxi. 2011;12(5):298-300.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dearnaley DP, Sydes MR, Graham JD, et al. Esclated - dose versus standard - dose conformal radioterapy in prostate cancer, first results from the MRC RTO1 randomised controlled trial. Lancet Oncol, 2007; 8(6): 475-487. Go to original source... Go to PubMed...
    2. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-terming results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases - free survival outcomes. Int. J. Radiat. Oncol. Biol.Phys. 2008; 71(4): 1028-1033. Go to original source... Go to PubMed...
    3. Jacob R, Hanlon AL, Horwitz EM, et al. The relationship of increasing radioterapy dose to reduce distant metastases and mortality in men with prostate cancer. Cancer 2004; 100(3): 538-543. Go to original source... Go to PubMed...
    4. Cox JD, Stetz J, Pajak TF, et al. Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31(5): 1341-1346. Go to original source... Go to PubMed...
    5. Pavy JJ, Damekamp J, Letschert J, et al. EORTS Late Effects Working Group. Late Effects toxicity scoring the Soma scale. Int. J. Radial. Oncol. Biol. Phys. 1995; 3(5): 1043-1047. Go to original source... Go to PubMed...
    6. Wachter S, Gerstner N, Goldner G, et al. Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol. 2000; 54(1): 11-19. Go to original source... Go to PubMed...
    7. Šefrová J, Paluska P, Odrážka K, Jirkovský V. Chronická gastrointestinální toxicita po zevní radioterapii karcinomu prostaty. Klin. Onkol. 2009; 22(5): 233-241. Go to PubMed...
    8. Kubeš J. Postavení radioterapie v léčbě karcinomu prostaty. Postgrad. med. 2010; 3: 300-304.
    9. Lukáš K. Idiopatické střevní záněty, Triton, 1997; ISBN 80-85875-31-4, s109-110.
    10. Garg AK, Mai WY, McGary JE, et al. Radiation proctopathy in the treatment of prostate cancer. Int. J. radiat. Oncol. Biol. Phys. 2006; 66(5): 1294-1305. Go to original source... Go to PubMed...
    11. Teshima T, Hanks GE, Hanlon AL, et al. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurence, response to treatment and duration of morbidity. Int. J. Radiat. Oncol. Biol. Phys. 1997; 39(1): 77-83. Go to original source... Go to PubMed...
    12. Fiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer preliminary results of a multicenter prospective study. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70(4): 1130-1137. Go to original source... Go to PubMed...
    13. Huang EH, Pollack A, Levy L, et al. Late rectal toxicity dosevolumen effects of conformal radiotherapy for prostate cancer. Int J. Radiat. Oncol. Biol. Phys. 2002; 54(5): 1314-1321. Go to original source... Go to PubMed...
    14. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Lokalized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64(4): 1151-1161. Go to original source... Go to PubMed...
    15. Song DY, Lawrie WT, Abrams RA, et al: Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 455-459. Go to original source... Go to PubMed...
    16. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three - dimensional conformal radiotherapy and intensity - modulated radiotherapy for localized prostate cancer. Int J. Radiat. Oncol. Biol. Phys. 2008; 70(4): 1124-1129. Go to original source... Go to PubMed...
    17. Perez CA, Brady LW, Halperin EC, et al. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins. 204; 357-361, 379-383.
    18. Lukáš K. Idiopatické střevní záněty, Triton, 1997; ISBN 80-85875-31-4, s109-110.
    19. Lukáš K. Průjem - diagnóza a léčba v praxi. Maxdorf 2002, ISBN 80-85912-59-7.
    20. Linke Z, Krausová J. Bolest vzniklá v souvislosti s radiační protinádorovou léčbou u onkologických pacientů. Bolest 2003; 6(2): 86-96.
    21. Lakomý R. Léčebný algoritmus akutních průjmovitých onemocnění způsobených onkologickou léčbou - chemoterapie, radioterapie, Diagnosticko-léčebné protokoly MOÚ, http://www.linkos.cz/odbornici/info_praxe/standardy.php.
    22. Delia P, Sanskrta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhoea. J. Gastroenterol. 2007; 13: 312-315. Go to original source...
    23. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of multicenter randomized trial. Int J Radiat Oncol Biol.Phys. 2005, 61(4): 1019-1034. Go to original source... Go to PubMed...
    24. ##
    25. Šefrová J, Paluska P, Odrážka K, et al. Chronická gastrointestinální toxicita po zevní radioterapii karcinomu prostaty. Klin Onkol. 2009; 22(5): 233-241. Go to PubMed...
    26. Dolezel M, Odrazka K, Vaculikova M, et al. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol. 2010; 186(4): 197-202. Go to original source... Go to PubMed...
    27. Odrazka K, Dolezel M, Vanasek J, et al. Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2010; 13(2): 138-143. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.